Navigation Links
Ovarian function and fertility preserved in women with severe systemic lupus erythematosus
Date:6/12/2008

Paris, France, Thursday 12 June 2008: Ovarian function can be preserved and disease activity controlled in women with severe systemic lupus erythematosus (SLE) when treated with a 6-month course of cyclophosphamide (CYC), a chemotherapy drug, followed by the immunosuppressant mycophenolate mofetil (MMF), according to a new study presented today at EULAR 2008, the Annual Congress of the European League Against Rheumatism in Paris, France.

SLE, a complex and unpredictable autoimmune disease, is characterised by chronic inflammation and damage of body tissues, including the heart, lungs, kidneys, joints, and/or nervous system. It is most common in women and, although long-term survival has dramatically improved over time with better diagnosis and treatment options, one of the challenges in managing the disease is to minimise the side-effects of treatments such as the disruption of ovarian function and risks to fertility. Pulsed intravenous CYC, a chemotherapeutic agent, is a standard therapy for SLE but may also be associated with ovarian failure in addition to other adverse effects.

Dr Katerina Laskari, the presenting author of the study, led by Professor Athanasios G Tzioufas in the Department of Pathophysiology of the National and Kapodistrian University of Athens, said: "Although the prognosis for people with SLE has considerably improved over the years, a patient's quality of life can all too often be seriously impaired by the toxicity of many commonly-used treatments. Preserving ovarian function is a very important consideration in treating women with SLE of child-bearing age, who are already burdened by the difficult nature and impact of the disease itself."

In this retrospective evaluation of 61 postmenopausal women with SLE treated for lupus nephritis (n=58), autoimmune hemolytic anemia (n=1) and central nervous system involvement (n=2), 39 patients received prolonged treatment with 1g/m2 intravenous (IV) CYC pulses (group A) for a median time of 24 months and 22 patients received 5-7 monthly 1g/m2 IV CYC pulses, followed by 2g/day MMF for a median time of 32 months (group B).

Results showed that disease activity was equally controlled using either treatment regimen (p=0.76 and p=0.31 for disease remission and relapse respectively), although patients in group A had a 4-fold higher risk of developing amenorrhea (absence of menstruation) compared with those in group B (p=0.001). 56% (n=22) of women in group A and 14% (n=3) in group B developed amenorrhea, while sustained amenorrhea developed in 51% (n=20/39) of women in group A vs 4% (n=1) in group B. 14% (3/22) of women in group A and 67% (2/3) in group B resumed menstruation following cessation of therapy.

Age (p<0.001), cumulative CYC dose (p=0.001) and anti-Ro antibodies (p=0.002) were significant in terms of amenorrhea. Sustained amenorrhea was related to both the form of treatment (p=0.006) and the age of the patients (p=0.026). The median total CYC dose until amenorrhea was 11 gr (range 2-29.5) and 3.7 gr (range 2-6.75) in group A and B respectively (p=0.036).

The median age of women with amenorrhea was 36 years (range 19-46) in group A and 33 years (range 27-45) in group B (p=0.71). It is of note that all patients aged >31 years developed amenorrhea with the long course CYC treatment and 94% did not resume menses until the end of follow up, whereas only 1 patient aged 45 years developed permanent amenorrhea with the short course CYC treatment.

SLE disease duration and ECLAM (European Consensus Lupus Activity Measurement) score were not significantly different in terms of amenorrhea (p≥0.05).


'/>"/>

Contact: Rory Berrie / Camilla Dormer
eularpressoffice@uk.cohnwolfe.com
44-077-892-70392
European League Against Rheumatism
Source:Eurekalert

Related medicine news :

1. A Knock-Out Match: Kelly Ripa and Molly Sims Team Up to Fight Ovarian Cancer
2. Coveting the Latest Clutch? Bid on a Bag and Help Fight Ovarian Cancer
3. Seattle-Based Marsha Rivkin Center for Ovarian Cancer Research Appoints Nancy Sclater, Executive Director
4. Stored Ovarian Tissue Needs Testing Before Re-Implantation
5. Cancer could return unless stored ovarian tissue undergoes adequate testing before re-implantation
6. Drug compound leads to death of ovarian cancer cells resistant to chemotherapy
7. FASgen Diagnostic Tests Identify Ovarian Cancer Progression and Apoptosis
8. Specialized Care for Ovarian Cancer Improves Outcomes
9. Recurrent low-grade carcinoma of the ovary less responsive to chemo than more common ovarian cancers
10. Advanced-stage ovarian cancer patients with BRCA live longer, may respond better to treatment
11. Gleevec May Disrupt Ovarian Function
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... ... May 03, 2016 , ... Diagnotes, ... by Tidelands Health, a three hospital system in South Carolina, to provide its ... lookout for technology that enhances communication, drives workflow efficiencies and improves provider and ...
(Date:5/3/2016)... (PRWEB) , ... May 03, 2016 , ... Park Cities ... live in or adjacent to the 75204, 75205, 75206, 75209, 75219, 75220, 75225, 75229, ... Greenway Parks, Bluffview, Midway Hollow, North Dallas, Plano, Preston Hollow and Park Cities areas ...
(Date:5/3/2016)... Corner, VA (PRWEB) , ... May 03, 2016 ... ... leading provider of innovative information technology (IT) solutions and digital consulting services to ... Enterprise Information Technology Services (EITS) Indefinite Delivery / Indefinite Quantity (ID/IQ) contract in ...
(Date:5/3/2016)... California (PRWEB) , ... May ... ... leading provider of Microsoft secure remote access connectivity solutions, today announced the ... platform for Microsoft DirectAccess. The new Celestix SecureAccess release will enable organizations ...
(Date:5/3/2016)... ... 2016 , ... Dave Newberry, broker/owner of Newberry Realty, recently announced his office ... luncheon on Friday, May 20. “We have raised over $1,000 for the table to ... Newberry. , PICC is a local Kent, WA, clinic that cares for drug-exposed babies ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... 2016  As a teenager, an active and athletic ... damaged his heart. He continued enjoying sports and recreation ... Shepherd,s heart was giving out and he was a ... 2013, the Mesa, Arizona resident ... a heart transplant, the SynCardia TAH-t is the only ...
(Date:5/3/2016)... , May 3, 2016  While you may be familiar with watching a film or TV ... known as ultra-high-definition or 8MP in the Medical Industry.  Ampronix  is a renowned authorized reseller ... technology. Photo - http://photos.prnewswire.com/prnh/20160502/362730 ... ... ...
(Date:5/3/2016)... , May 3, 2016 ... pay $55 million to a woman who says its ... court awarded Gloria Ristesund $5 million in ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ... accusations against the company. In February, the same court ...
Breaking Medicine Technology: